These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 35941674)

  • 41. Radiomics-based nomogram guides adaptive de-intensification in locoregionally advanced nasopharyngeal carcinoma following induction chemotherapy.
    Wang SX; Yang Y; Xie H; Yang X; Liu ZQ; Li HJ; Huang WJ; Luo WJ; Lei YM; Sun Y; Ma J; Chen YF; Liu LZ; Mao YP
    Eur Radiol; 2024 Oct; 34(10):6831-6842. PubMed ID: 38514481
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
    Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
    Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
    Tang LL; Guo R; Zhang N; Deng B; Chen L; Cheng ZB; Huang J; Hu WH; Huang SH; Luo WJ; Liang JH; Zheng YM; Zhang F; Mao YP; Li WF; Zhou GQ; Liu X; Chen YP; Xu C; Lin L; Liu Q; Du XJ; Zhang Y; Sun Y; Ma J
    JAMA; 2022 Aug; 328(8):728-736. PubMed ID: 35997729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction Chemotherapy Followed by Radiotherapy versus Concurrent Chemoradiotherapy in elderly patients with nasopharyngeal carcinoma: finding from a propensity-matched analysis.
    Zeng Q; Wang J; Lv X; Li J; Yin LJ; Xiang YQ; Guo X
    BMC Cancer; 2016 Aug; 16(1):693. PubMed ID: 27577729
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The efficacy of adjuvant chemotherapy in patients with different midpoint-radiotherapy Epstein-Barr virus DNA plasma loads.
    Chen J; Cheng H; Liang Y; Lin J; Jia G; Wang T; Li Y; Chen Y; Wang P; Shen B; Liu S; Guo S; Chen Q; Tang L; Mai H; Liu L
    Oral Oncol; 2024 Sep; 156():106938. PubMed ID: 38970970
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diffusion-Weighted Magnetic Resonance Imaging-Guided Dose Painting in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Plus Concurrent Chemoradiotherapy: A Randomized, Controlled Clinical Trial.
    Fu S; Li Y; Han Y; Wang H; Chen Y; Yan O; He Q; Ma H; Liu L; Liu F
    Int J Radiat Oncol Biol Phys; 2022 May; 113(1):101-113. PubMed ID: 35074433
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Integrating pretreatment MRI-detected nodal features and Epstein-Barr virus DNA to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma.
    Guo J; He Y; Lin C; Jiang Q; Xing HW; Zhang YC; Shen GZ; Lin HX; Guo L; Yang Q
    Oral Oncol; 2023 Nov; 146():106574. PubMed ID: 37741017
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impairment of induction chemotherapy for stage II nasopharyngeal carcinoma treated with intensity-modulated radiotherapy with or without concurrent chemotherapy: A propensity score-matched analysis.
    Lai Y; Wang C; Yang X; He S; Wang Y; Chen Y
    Cancer Med; 2023 Feb; 12(3):2970-2978. PubMed ID: 36114787
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage III nasopharyngeal carcinoma based on propensity score-matching.
    Liu ZC; Zeng KH; Gu ZB; Chen RP; Luo YJ; Tang LQ; Zhu KB; Liu Y; Sun XS; Zeng L
    Radiother Oncol; 2023 Jan; 178():109421. PubMed ID: 36410548
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level.
    Liu SL; Sun XS; Xie HJ; Chen QY; Lin HX; Liang H; Liang YJ; Li XY; Yan JJ; Lin C; Yang ZC; Guo SS; Liu LT; Tang QN; Du YY; Tang LQ; Guo L; Mai HQ
    BMC Cancer; 2020 Feb; 20(1):89. PubMed ID: 32013967
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
    Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
    Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does three cycles of neoadjuvant chemotherapy prior to concurrent chemoradiotherapy provide benefits for all childhood patients with locoregionally advanced nasopharyngeal carcinoma?
    Jin YN; Cao HJ; Gong XH; Zhang WJ; Marks T; Yao JJ; Xia LP
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2569-2579. PubMed ID: 34618220
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pretreatment Plasma EBV-DNA Load Guides Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Cancer: A Meta-Analysis.
    Lai L; Chen X; Zhang C; Chen X; Chen L; Tian G; Zhu X
    Front Oncol; 2020; 10():610787. PubMed ID: 33665166
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
    Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
    Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus-Related Nasopharyngeal Carcinoma.
    Li WZ; Wu HJ; Lv SH; Hu XF; Liang H; Liu GY; Lu N; Bei WX; Lv X; Guo X; Xia WX; Xiang YQ
    JAMA Netw Open; 2021 Sep; 4(9):e2124721. PubMed ID: 34554238
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proposed prognostic subgroups and facilitated clinical decision-making for additional locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: a retrospective study based on recursive partitioning analysis.
    Yao Y; Sun X; Huang H; Wang Z; Fang X; Chen M; Chen Z; Weng H; Guo C; Hong H; Huang H; Lin T
    Radiat Oncol; 2023 Jan; 18(1):15. PubMed ID: 36681832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Significance of chemotherapy for older patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A propensity score matching analysis.
    Chen J; Ding J; Xu Y; Hong H; Lin X; Xu M; Yan L; Xu T; Fei Z; Chen C
    J Geriatr Oncol; 2023 Nov; 14(8):101648. PubMed ID: 37897887
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
    Li PJ; Mo HY; Luo DH; Hu WH; Jin T
    Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
    Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
    Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Significance of boost dose for T4 nasopharyngeal carcinoma with residual primary lesion after intensity-modulated radiotherapy.
    Fei Z; Xu T; Qiu X; Li M; Chen T; Li L; Huang C; Chen C
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2047-2055. PubMed ID: 33392660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.